CN108727335A - A kind of purification method of bepotastine besilate - Google Patents
A kind of purification method of bepotastine besilate Download PDFInfo
- Publication number
- CN108727335A CN108727335A CN201810891851.8A CN201810891851A CN108727335A CN 108727335 A CN108727335 A CN 108727335A CN 201810891851 A CN201810891851 A CN 201810891851A CN 108727335 A CN108727335 A CN 108727335A
- Authority
- CN
- China
- Prior art keywords
- bepotastine
- benzene sulphur
- sulphur bepotastine
- purification process
- silica gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000746 purification Methods 0.000 title claims abstract description 30
- UDGHXQPQKQPSBB-UHFFFAOYSA-N benzenesulfonic acid;4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1CN(CCCC(=O)O)CCC1OC(C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 UDGHXQPQKQPSBB-UHFFFAOYSA-N 0.000 title abstract description 26
- 229960001105 bepotastine besilate Drugs 0.000 title abstract description 26
- 238000000034 method Methods 0.000 title abstract description 9
- 229960002071 bepotastine Drugs 0.000 claims abstract description 56
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 claims abstract description 54
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000000741 silica gel Substances 0.000 claims abstract description 25
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 25
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 12
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 12
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 12
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 12
- 229960004853 betadex Drugs 0.000 claims abstract description 12
- 239000012043 crude product Substances 0.000 claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- 239000003960 organic solvent Substances 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 2
- 239000012044 organic layer Substances 0.000 claims description 2
- 229940090181 propyl acetate Drugs 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- AHIBWURJLGCHAY-UHFFFAOYSA-N [S].C1=CC=CC=C1 Chemical compound [S].C1=CC=CC=C1 AHIBWURJLGCHAY-UHFFFAOYSA-N 0.000 claims 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 239000005864 Sulphur Substances 0.000 claims 3
- 238000013019 agitation Methods 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 239000012535 impurity Substances 0.000 abstract description 11
- 238000004440 column chromatography Methods 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003463 adsorbent Substances 0.000 abstract 1
- 238000001953 recrystallisation Methods 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 5
- UDGHXQPQKQPSBB-BOXHHOBZSA-N bepotastine besylate Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 UDGHXQPQKQPSBB-BOXHHOBZSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000009776 industrial production Methods 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- JFJSYIUZTRGWSW-UHFFFAOYSA-N benzenesulfonic acid;butanoic acid Chemical compound CCCC(O)=O.OS(=O)(=O)C1=CC=CC=C1 JFJSYIUZTRGWSW-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域technical field
本发明属于药物分离纯化技术领域,具体涉及一种苯磺贝他斯汀的纯化方法。The invention belongs to the technical field of separation and purification of medicines, and in particular relates to a purification method of bepotastine besilate.
背景技术Background technique
苯磺贝他斯汀(Bepotastine Beslilate),化学名为:4-[4-[(S)-[(4-氯苯基)吡啶-2-基]甲氧基]哌啶-1-基]丁酸单苯磺酸盐,分子量为547.06,CAS号为:190786-44-8,其结构式如下:Bepotastine Beslilate, chemical name: 4-[4-[(S)-[(4-chlorophenyl)pyridin-2-yl]methoxy]piperidin-1-yl] Butyric acid monobenzenesulfonate, the molecular weight is 547.06, the CAS number is: 190786-44-8, and its structural formula is as follows:
。 .
苯磺贝他斯汀是日本田边(Tanabe Seiyaku)公司和日本宇部(Ube Industries)公司联合开发的组胺H-1受体拮抗剂,其对组胺H1受体有高度选择性。还有研究发现,苯磺贝他斯汀能抑制嗜酸粒细胞浸润至外周组织,因此能缓解鼻粘膜的炎症反应。另外,苯磺贝他斯汀很少进入脑内,无镇静作用,抗胆碱作用与抗组胺作用相分离,其它不良反应极小,具有优良的药效学作用和临床效果,作用强度优于酮替芬、特非那定、西替立嗪、依匹那丁,因此临床应用前景广阔。Bepotastine bepotastine is a histamine H-1 receptor antagonist jointly developed by Japan's Tanabe Seiyaku and Japan's Ube Industries, which is highly selective for histamine H1 receptors. Other studies have found that bepotastine bepotastine can inhibit the infiltration of eosinophils into peripheral tissues, thereby alleviating the inflammatory response of the nasal mucosa. In addition, bepotastine besilate rarely enters the brain, has no sedative effect, the anticholinergic effect is separated from the antihistamine effect, and other adverse reactions are minimal. In ketotifen, terfenadine, cetirizine, epinadine, so the prospect of clinical application is broad.
现有研究显示,苯磺贝他斯汀不同异构体在药理作用上的显著差异,其中S异构体比R异构体药理作用强100倍以上,且S异构体血浆蛋白结合率比R型高,故作为杂质的苯磺贝他斯汀中R异构体的含量越少越好。现有文献中没有专门关于苯磺贝他斯汀纯化的报道,常采用重结晶法进行纯化。重结晶法虽然可以得到纯度95%的苯磺贝他斯汀,但是要进一步纯化得到纯度99.5%以上的苯磺贝他斯汀,同时使光学异构体控制在检测限以下,现有纯化方法还无法实现。因此急需提出新的方案对苯磺贝他斯汀进行有效纯化。Existing studies have shown that there are significant differences in the pharmacological effects of different isomers of bepotastine besilate, among which the pharmacological effect of the S isomer is more than 100 times stronger than that of the R isomer, and the plasma protein binding rate of the S isomer is higher than that of the R isomer. The R type is high, so the less the R isomer content in bepotastine bepotastine as an impurity, the better. There is no special report on the purification of bepotastine besilate in the existing literature, and recrystallization is often used for purification. Although the recrystallization method can obtain bepotastine bepotastine with a purity of 95%, it needs to be further purified to obtain bepotastine with a purity of more than 99.5%, while keeping the optical isomers below the detection limit. Not yet possible. Therefore, it is urgent to propose a new scheme to effectively purify bepotastine besilate.
发明内容Contents of the invention
本发明针对现有技术存在的问题,提供了一种可有效提高苯磺贝他斯汀纯度,且可操作性好、适合于大规模工业化生产的纯化方法。Aiming at the problems existing in the prior art, the present invention provides a purification method that can effectively improve the purity of bepotastine besilate, has good operability and is suitable for large-scale industrial production.
为实现上述目的,本发明采用如下技术方案:To achieve the above object, the present invention adopts the following technical solutions:
一种苯磺贝他斯汀的纯化方法,其包括以下步骤:A purification method of bepotastine besilate, which comprises the following steps:
1)将苯磺贝他斯汀粗品溶解于有机溶剂中,形成苯磺贝他斯汀溶液;1) Dissolving the crude product of bepotastine besilate in an organic solvent to form a bepotastine besilate solution;
2)将β-环糊精键合硅胶用有机溶剂溶散,形成键合硅胶溶液;2) Dissolve β-cyclodextrin bonded silica gel with an organic solvent to form a bonded silica gel solution;
3)在搅拌条件下将苯磺贝他斯汀溶液滴入键合硅胶溶液中,过滤、水洗后取有机层浓缩至干,得到纯化的苯磺贝他斯汀。3) Drop the bepotastine bepotastine solution into the bonded silica gel solution under stirring conditions, filter and wash with water, then take the organic layer and concentrate to dryness to obtain purified bepotastine bepotastine.
所述苯磺贝他斯汀粗品的纯度为95%-98%,光学纯度为0.5%-1%。The purity of the crude bepotastine besilate is 95%-98%, and the optical purity is 0.5%-1%.
所用β-环糊精键合硅胶与苯磺贝他斯汀粗品的重量比为3-4:1,以保证充分去除杂质,并避免β-环糊精键合硅胶用量过大而导致的溶剂用量的增加以及收率的降低。The weight ratio of the β-cyclodextrin-bonded silica gel to the crude product of bepotastine besilate is 3-4:1 to ensure sufficient removal of impurities and to avoid solvent contamination caused by excessive use of β-cyclodextrin-bonded silica gel. An increase in dosage and a decrease in yield.
有机溶剂加入量过多可能导致杂质不能吸附完全,加入量过少可能导致收率降低,因此,操作中所用有机溶剂与苯磺贝他斯汀粗品的重量比为5-20:1;其中,所述有机溶剂为正丁醇、乙酸乙酯、二氯甲烷中的一种或几种,优选乙酸乙酯。Too much addition of organic solvent may cause impurities to be unable to absorb completely, and too little addition may cause yield reduction. Therefore, the weight ratio of organic solvent used in the operation to the crude product of bepotastine besilbestatin is 5-20:1; wherein, The organic solvent is one or more of n-butanol, ethyl acetate and dichloromethane, preferably ethyl acetate.
步骤3)中滴加的时间控制在1-2小时。The time of dropping in step 3) is controlled within 1-2 hours.
步骤3)采用过滤除去吸附杂质的固形物时,滤饼可用乙酸乙酯清洗,以使滤饼中的苯磺贝他斯汀洗出;清洗时优选0-5℃的乙酸乙酯,其可有效洗出苯磺贝他斯汀而不洗脱杂质,达到较佳的分离效果。Step 3) When filtration is used to remove the solid matter of adsorbed impurities, the filter cake can be washed with ethyl acetate to wash out the bepotastine besil in the filter cake; ethyl acetate at 0-5°C is preferred for cleaning, which can Effectively wash out bepotastine besilate without eluting impurities, achieving better separation effect.
步骤3)中所述水洗是在滤液中加入其体积0.2-0.3倍的水清洗两次,以除去有机相中可能混有的β-环糊精等杂质。The water washing in step 3) is to add 0.2-0.3 times the volume of water to the filtrate to wash twice, so as to remove impurities such as β-cyclodextrin that may be mixed in the organic phase.
经上述步骤纯化后,所得苯磺贝他斯汀的纯度可达99.5%,其还可经重结晶进一步纯化,其具体步骤为:将所得纯化的苯磺贝他斯汀于溶剂中加热溶解,然后将其降温至0-20℃,使其析出固体,再经过滤、干燥得到高纯度苯磺贝他斯汀。After purification through the above steps, the purity of bepotastine bepotastine obtained can reach 99.5%, and it can be further purified by recrystallization. The specific steps are: heating and dissolving the obtained purified bepotastine in a solvent, Then lower the temperature to 0-20°C to precipitate solids, and then filter and dry to obtain high-purity bepotastine besilate.
所述溶剂与纯化的的苯磺贝他斯汀的重量比为5-20:1;其中,所述溶剂为丙酮、乙酸乙酯、乙酸丙酯、甲醇、乙醇、异丙醇、正己烷、正庚烷中的一种或几种。The weight ratio of the solvent to the purified bepotastine bepotastine is 5-20:1; wherein the solvent is acetone, ethyl acetate, propyl acetate, methanol, ethanol, isopropanol, n-hexane, One or more of n-heptane.
本发明的显著优点在于:Significant advantage of the present invention is:
(1)本发明中将苯磺贝他斯汀粗品溶解于有机溶剂,再用β-环糊精键合硅胶对溶液中的绝大部分杂质进行有效吸附,而不影响目标物苯磺贝他斯汀,再采用过滤和浓缩的方法得到纯度99.5%以上的苯磺贝他斯汀。经进一步重结晶纯化后,能够有效去除苯磺贝他斯汀粗品中的杂质和异构体,所得高纯度苯磺贝他斯汀的纯度可达99.9%,R异构体杂质低于检测限。(1) In the present invention, the crude product of bepotastine besilate is dissolved in an organic solvent, and then β-cyclodextrin-bonded silica gel is used to effectively adsorb most of the impurities in the solution without affecting the target product bepotastine Bepotastine bepotastine with a purity of more than 99.5% is obtained by filtering and concentrating. After further recrystallization and purification, the impurities and isomers in the crude product of bepotastine besylate can be effectively removed, and the purity of the obtained high-purity bepotastine besylate can reach 99.9%, and the R isomer impurity is lower than the detection limit .
(2)本发明无需采用操作难度大、不适合工业化生产的硅胶柱层析方法进行纯化,仅利用β-环糊精键合硅胶吸附以及重结晶方法进行纯化,其纯化过程操作简便,操作时间短,对操作人员要求不高,并省去了大量有机溶剂的使用,且产品收率高,纯度高,异构体也降到检测限附近,适用于高纯度苯磺贝他斯汀规模化工业生产。(2) The present invention does not need to adopt the silica gel column chromatography method which is difficult to operate and is not suitable for industrial production for purification, but only uses β-cyclodextrin-bonded silica gel adsorption and recrystallization methods for purification. The purification process is easy to operate and takes less time to operate. Short, low requirements for operators, and save the use of a large number of organic solvents, and the product yield is high, high purity, isomers are also reduced to near the detection limit, suitable for large-scale production of high-purity bepotastine besilate industrial production.
具体实施方式Detailed ways
为了使本发明所述的内容更加便于理解,下面结合具体实施方式对本发明所述的技术方案做进一步的说明,但是本发明不仅限于此。In order to make the content of the present invention easier to understand, the technical solutions of the present invention will be further described below in conjunction with specific embodiments, but the present invention is not limited thereto.
在50L反应釜中,加入无水二甲基甲酰胺30L和0.5kg干燥过的β-环糊精,并加入2.5g金属钠,搅拌混合;称取5kg柱层析用硅胶、0.05kg经干燥过的3-缩水甘油基氧丙基三甲氧基硅烷,加入反应釜中,搅拌混合;升温至105℃,反应12小时,过滤,滤饼用无水二甲基甲酰胺、丙酮、水各洗三次,60℃条件下减压干燥5小时,得到β-环糊精键合硅胶。In a 50L reaction kettle, add 30L of anhydrous dimethylformamide and 0.5kg of dried β-cyclodextrin, and add 2.5g of sodium metal, stir and mix; weigh 5kg of silica gel for column chromatography, 0.05kg of dried Add the 3-glycidyloxypropyltrimethoxysilane to the reaction kettle, stir and mix; raise the temperature to 105°C, react for 12 hours, filter, and wash the filter cake with anhydrous dimethylformamide, acetone, and water Three times, drying under reduced pressure at 60° C. for 5 hours to obtain β-cyclodextrin-bonded silica gel.
其中,所用柱层析硅胶为100-300目,优选200-300目,较细硅胶具有较好的杂质吸附效果,而且分离和过滤较容易。Wherein, the column chromatography silica gel used is 100-300 mesh, preferably 200-300 mesh, and finer silica gel has better impurity adsorption effect, and is easier to separate and filter.
1. β-环糊精键合硅胶吸附纯化苯磺贝他斯汀粗品1. Purification of crude bepotastine besilate by adsorption on β-cyclodextrin bonded silica gel
将乙酸乙酯和苯磺贝他斯汀粗品加入玻璃瓶中,搅拌溶解后得到苯磺贝他斯汀溶液,备用;将β-环糊精键合硅胶和乙酸乙酯投入反应釜中,搅拌溶散后得到键合硅胶溶液;在搅拌条件下将苯磺贝他斯汀溶液滴入键合硅胶溶液中,滴加时间1-2小时;然后过滤,滤饼用乙酸乙酯清洗后合并滤液和洗液,加入其体积0.2-0.3倍的水洗两次,取乙酸乙酯层浓缩至干,得到苯磺贝他斯汀。Add ethyl acetate and crude bepotastine bepotastine into a glass bottle, stir and dissolve to obtain a solution of bepotastine besilate for later use; put β-cyclodextrin bonded silica gel and ethyl acetate into the reaction kettle, stir After dissolving, a bonded silica gel solution is obtained; drip bepotastine bepotastine solution into the bonded silica gel solution under stirring conditions, and the dropping time is 1-2 hours; then filter, the filter cake is washed with ethyl acetate and the filtrate is combined and washing solution, add 0.2-0.3 times the volume of water to wash twice, take the ethyl acetate layer and concentrate to dryness to obtain bepotastine besilate.
上述操作中,苯磺贝他斯汀粗品投料量、纯度、反应釜容积、溶剂用量、β-环糊精键合硅胶用量及经β-环糊精键合硅胶吸附纯化后得到的苯磺贝他斯汀的纯化结果如表1实施例1-5所示。In the above operation, the amount of crude product of bepotastine bepotastine, purity, reaction kettle volume, solvent usage, dosage of β-cyclodextrin bonded silica gel and the amount of bepotastine obtained after adsorption and purification of β-cyclodextrin bonded silica gel The purification results of stastatin are shown in Table 1, Examples 1-5.
表1 β-环糊精键合硅胶吸附纯化苯磺贝他斯汀粗品的参数及结果Table 1 Parameters and results of purification of crude bepotastine besilate by adsorption on β-cyclodextrin bonded silica gel
由表1可见,纯度95.1%-97.6%、异构体含量0.82%-0.99%的苯磺贝他斯汀粗品经过β-环糊精键合硅胶纯化后,苯磺贝他斯汀纯度得到大幅提升,纯度均达到99.5%以上,同时异构体含量也降到0.3%以下,符合苯磺贝他斯汀原料药质量标准的基本要求。It can be seen from Table 1 that after the crude product of bepotastine bepotastine with a purity of 95.1%-97.6% and an isomer content of 0.82%-0.99% was purified by β-cyclodextrin-bonded silica gel, the purity of bepotastine besilate was greatly improved. Improvement, the purity reaches more than 99.5%, and the isomer content is also reduced to less than 0.3%, which meets the basic requirements of the quality standard of bepotastine besilate raw material.
2. 重结晶纯化苯磺贝他斯汀2. Purification of bepotastine besilate by recrystallization
将上述制得的苯磺贝他斯汀用有机溶剂加热回流溶解,降温至T℃析出固体,过滤、干燥得到高纯度苯磺贝他斯汀,其纯化效果见表2。The bepotastine bepotastine prepared above was dissolved in an organic solvent under reflux, cooled to T°C to precipitate a solid, filtered, and dried to obtain high-purity bepotastine bepotastine. The purification effect is shown in Table 2.
表2苯磺贝他斯汀进一步纯化的参数及结果Table 2 Parameters and results of further purification of bepotastine besilate
由表2可见,所得苯磺贝达他斯汀经进一步重结晶纯化后,所得成品的纯度均达到99.9%以上,成品中异构体均为未检出(低于最低检出限)。It can be seen from Table 2 that after further recrystallization and purification of the obtained bedastatin besylate, the purity of the obtained finished products all reached above 99.9%, and no isomers were detected in the finished products (below the minimum detection limit).
以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。The above descriptions are only preferred embodiments of the present invention, and all equivalent changes and modifications made according to the scope of the patent application of the present invention shall fall within the scope of the present invention.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810891851.8A CN108727335A (en) | 2018-08-07 | 2018-08-07 | A kind of purification method of bepotastine besilate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810891851.8A CN108727335A (en) | 2018-08-07 | 2018-08-07 | A kind of purification method of bepotastine besilate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108727335A true CN108727335A (en) | 2018-11-02 |
Family
ID=63942374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810891851.8A Pending CN108727335A (en) | 2018-08-07 | 2018-08-07 | A kind of purification method of bepotastine besilate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108727335A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1242013A (en) * | 1996-12-26 | 2000-01-19 | 宇部兴产株式会社 | Acid addition salts of optically active piperidine compounds and process for preparing the same |
| US20140046068A1 (en) * | 2012-08-10 | 2014-02-13 | Everlight Usa, Inc. | Method of synthesizing bepotastine or benzenesulfonic acid salt thereof and intermediates used therein |
| CN106117183A (en) * | 2016-06-24 | 2016-11-16 | 合肥久诺医药科技有限公司 | A kind of process for purification of high-purity benzene sulphur bepotastine |
-
2018
- 2018-08-07 CN CN201810891851.8A patent/CN108727335A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1242013A (en) * | 1996-12-26 | 2000-01-19 | 宇部兴产株式会社 | Acid addition salts of optically active piperidine compounds and process for preparing the same |
| US20140046068A1 (en) * | 2012-08-10 | 2014-02-13 | Everlight Usa, Inc. | Method of synthesizing bepotastine or benzenesulfonic acid salt thereof and intermediates used therein |
| CN106117183A (en) * | 2016-06-24 | 2016-11-16 | 合肥久诺医药科技有限公司 | A kind of process for purification of high-purity benzene sulphur bepotastine |
Non-Patent Citations (2)
| Title |
|---|
| 夏俊等: "苯磺酸贝他斯汀的合成新方法", 《中国医药工业杂志》 * |
| 白熙等: "不同交联剂对羟乙基β-环糊精固定相选择性的影响", 《长治医学院学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105440040B (en) | The purification process of Buddhist nun is replaced according to Shandong | |
| CN105085373B (en) | Purification method of apremilast product | |
| CN113292533A (en) | Method for purifying polymer impurities in lipoic acid | |
| CN106256824B (en) | Preparation method of high-purity delafloxacin meglumine salt | |
| CN105418581A (en) | Preparation method of trelagliptin succinate | |
| CN110655511B (en) | Preparation and refining method of high-purity empagliflozin | |
| CN102351847B (en) | Industrial method for refining esomeprazole sodium salt | |
| CN102775387B (en) | Method for refining fasudil hydrochloride | |
| WO2020207130A1 (en) | Process for separating and purifying artemisinin | |
| CN105481856A (en) | Preparation method of palipefidone | |
| CN103044323B (en) | A kind of purification process of SASP | |
| CN108727335A (en) | A kind of purification method of bepotastine besilate | |
| CN106543025A (en) | A kind of preparation method of high-purity hydrochloric acid doxycycline | |
| CN103613579A (en) | Bilastine purifying method | |
| WO2022142385A1 (en) | Method for refining dienogest | |
| CN101560188B (en) | Method for separating and purifying 2-methylimidazole crystal impurity | |
| CN108976224B (en) | Method for extracting and purifying ergometrine from fermentation liquor | |
| CN116396146B (en) | A continuous crystallization method for cannabidiol | |
| CN103588841B (en) | The process for purification of trihydroxy-oestrin | |
| CN111153862B (en) | A kind of refining method of Recinade | |
| WO2023138341A1 (en) | Synthesis method for ertapenem sodium | |
| CN110606844B (en) | Mupirocin purification method | |
| CN102391094A (en) | Crystallization method for preparing high-purity idebenone | |
| CN104892501A (en) | Aftertreatment purification method for 3-[(3-amino-4-methylamino benzoyl)(pyridine-2-yl)amino]ethyl propionate | |
| CN116396346B (en) | A method for reducing free fatty acids in dexamethasone palmitate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181102 |
|
| RJ01 | Rejection of invention patent application after publication |